IL126902A - Tetrahydrolipstatin containing compositions - Google Patents
Tetrahydrolipstatin containing compositionsInfo
- Publication number
- IL126902A IL126902A IL12690298A IL12690298A IL126902A IL 126902 A IL126902 A IL 126902A IL 12690298 A IL12690298 A IL 12690298A IL 12690298 A IL12690298 A IL 12690298A IL 126902 A IL126902 A IL 126902A
- Authority
- IL
- Israel
- Prior art keywords
- weight
- composition
- pellets
- polyvinylpyrrolidone
- tetrahydrolipstatin
- Prior art date
Links
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 title claims abstract description 35
- 229960001243 orlistat Drugs 0.000 title claims abstract description 10
- AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 title claims abstract description 9
- 239000000203 mixture Substances 0.000 title claims description 33
- 239000008188 pellet Substances 0.000 claims abstract description 44
- 239000002245 particle Substances 0.000 claims abstract description 26
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 16
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 16
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 16
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 16
- 239000003381 stabilizer Substances 0.000 claims abstract description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 22
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 22
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 20
- 239000008109 sodium starch glycolate Substances 0.000 claims description 12
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 12
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 11
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 239000000454 talc Substances 0.000 claims description 8
- 229910052623 talc Inorganic materials 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000007884 disintegrant Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 229920002261 Corn starch Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 2
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000000463 material Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- -1 for example Substances 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 238000005563 spheronization Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 241000275031 Nica Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000012798 spherical particle Substances 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 229940122816 Amylase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3738497P | 1997-02-05 | 1997-02-05 | |
| US09/003,137 US6004996A (en) | 1997-02-05 | 1998-01-06 | Tetrahydrolipstatin containing compositions |
| PCT/EP1998/000395 WO1998034607A1 (en) | 1997-02-05 | 1998-01-24 | Tetrahydrolipstatin containing compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL126902A0 IL126902A0 (en) | 1999-09-22 |
| IL126902A true IL126902A (en) | 2002-12-01 |
Family
ID=26671373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12690298A IL126902A (en) | 1997-02-05 | 1998-01-24 | Tetrahydrolipstatin containing compositions |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6004996A (de) |
| EP (1) | EP0921796B1 (de) |
| CN (1) | CN1193752C (de) |
| AR (1) | AR010704A1 (de) |
| AT (1) | ATE200027T1 (de) |
| AU (1) | AU713192B2 (de) |
| CA (1) | CA2258095C (de) |
| CO (1) | CO4920214A1 (de) |
| CY (1) | CY2264B1 (de) |
| CZ (1) | CZ287154B6 (de) |
| DE (1) | DE69800639T2 (de) |
| DK (1) | DK0921796T3 (de) |
| ES (1) | ES2156028T3 (de) |
| GR (1) | GR3036064T3 (de) |
| HR (1) | HRP980057B1 (de) |
| HU (1) | HU225035B1 (de) |
| ID (1) | ID26509A (de) |
| IL (1) | IL126902A (de) |
| MA (1) | MA24466A1 (de) |
| MY (1) | MY118371A (de) |
| NO (1) | NO320445B1 (de) |
| NZ (1) | NZ332659A (de) |
| PE (1) | PE57599A1 (de) |
| PT (1) | PT921796E (de) |
| RU (1) | RU2170579C2 (de) |
| SI (1) | SI0921796T1 (de) |
| UY (1) | UY24875A1 (de) |
| WO (1) | WO1998034607A1 (de) |
| YU (1) | YU49423B (de) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL191222B1 (pl) * | 1997-02-05 | 2006-03-31 | Hoffmann La Roche | Zastosowanie tetrahydrolipstatyny do wytwarzania doustnego farmaceutycznego preparatu do leczenia cukrzycy typu II |
| CA2340056C (en) | 1998-08-14 | 2007-01-09 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions containing lipase inhibitors |
| AU745697B2 (en) * | 1998-09-08 | 2002-03-28 | Smithkline Beecham Corporation | Lipstatin derivative-soluble fiber tablets |
| AR025609A1 (es) * | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones lipidas solidas |
| AR025587A1 (es) * | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones en dispersion que contienen inhibidores de lipasa |
| EP1132389A1 (de) | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | Neue Azaindolyl-Derivate für die Behandlung von Fettleibigheit |
| DE10021618A1 (de) * | 2000-05-04 | 2001-11-15 | Volker Helmstaedter | Präparat für Darmerkrankungen und dessen Verwendung |
| ES2269441T3 (es) * | 2000-06-27 | 2007-04-01 | F. Hoffmann-La Roche Ag | Metodo para la preparacion de una composicion. |
| KR100572785B1 (ko) * | 2000-07-28 | 2006-04-19 | 에프. 호프만-라 로슈 아게 | 신규한 약학 조성물 |
| ATE293477T1 (de) | 2000-07-28 | 2005-05-15 | Hoffmann La Roche | Neue verwendung von lipase-inhibitoren |
| CA2417607C (en) | 2000-08-09 | 2008-01-29 | Christine Feinle | Lipase inhibitors for the treatment of dyspepsia |
| US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| WO2002044152A1 (en) | 2000-10-16 | 2002-06-06 | F. Hoffmann-La Roche Ag | Indoline derivatives and their use as 5-ht2 receptor ligands |
| GB0030710D0 (en) * | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
| BR0116605A (pt) | 2000-12-27 | 2003-09-30 | Hoffmann La Roche | Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono |
| GB0106177D0 (en) * | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| AU2002338896B2 (en) * | 2001-05-21 | 2006-04-27 | F.Hoffman-La Roche Ag | Quinoline derivatives as ligands for the neuropeptide Y receptor |
| US20030027786A1 (en) * | 2001-06-06 | 2003-02-06 | Karsten Maeder | Lipase inhibiting composition |
| US6787558B2 (en) * | 2001-09-28 | 2004-09-07 | Hoffmann-La Roche Inc. | Quinoline derivatives |
| US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
| US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
| US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| DE10152351B4 (de) * | 2001-10-18 | 2005-09-22 | Schering Ag | Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat |
| WO2003039516A1 (en) * | 2001-11-07 | 2003-05-15 | Fujisawa Pharmaceuticla Co., Ltd. | Method for improving dissolution of poorly dispersible medicaments |
| ATE333270T1 (de) * | 2001-12-20 | 2006-08-15 | Alpex Pharma Sa | Pharmazeutische zusammensetzung enthaltend magermilchpulver |
| GB0202015D0 (en) * | 2002-01-29 | 2002-03-13 | Hoffmann La Roche | Piperazine Derivatives |
| PL372295A1 (en) * | 2002-02-04 | 2005-07-11 | F.Hoffmann-La Roche Ag | Quinoline derivatives as npy antagonists |
| BR0308108A (pt) | 2002-02-28 | 2004-12-07 | Hoffmann La Roche | Compostos; processo para a preparação de composto; composição farmacêutica que compreende o mesmo, utilização dos compostos e método de tratamento e profilaxia de enfermidades e de obesidade |
| PL216022B1 (pl) * | 2002-04-26 | 2014-02-28 | Hoffmann La Roche | Kompozycja farmaceutyczna, sposób jej wytwarzania i jej zastosowanie, zestaw do leczenia otylosci, inhibitor lipazy w postaci orlistatu i glukomannan lub konjac, zastosowanie inhibitora lipazy w postaci orlistatu oraz zastosowanie glukomannanu lub konjacu |
| CA2489251A1 (en) * | 2002-07-05 | 2004-01-15 | F. Hoffmann-La Roche Ag | Quinazoline derivatives |
| AU2003253364B2 (en) * | 2002-08-07 | 2007-06-07 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
| WO2004024726A1 (en) * | 2002-09-12 | 2004-03-25 | F. Hoffmann-La Roche Ag | N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes |
| DE60323130D1 (de) * | 2002-11-25 | 2008-10-02 | Hoffmann La Roche | Indolderivaten |
| US20040178058A1 (en) * | 2003-03-10 | 2004-09-16 | Hsueh-Chung Chen | Electro-chemical deposition apparatus and method of preventing cavities in an ECD copper film |
| GB0314967D0 (en) * | 2003-06-26 | 2003-07-30 | Hoffmann La Roche | Piperazine derivatives |
| CA2533463A1 (en) * | 2003-08-12 | 2005-02-17 | F. Hoffmann-La Roche Ag | 2-amino-5-benzoylthiazole npy antagonists |
| CN100393718C (zh) * | 2003-08-12 | 2008-06-11 | 霍夫曼-拉罗奇有限公司 | 作为npy拮抗剂的噻唑衍生物 |
| WO2006110809A2 (en) * | 2005-04-12 | 2006-10-19 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
| CA2609634C (en) * | 2005-05-03 | 2011-02-01 | F. Hoffmann-La Roche Ag | Tetracyclic azapyrazinoindolines as 5-ht2 ligands |
| KR100910000B1 (ko) * | 2005-05-13 | 2009-07-29 | 씨제이제일제당 (주) | 리파아제 저해제 함유 약학 조성물 |
| JP5044398B2 (ja) * | 2005-06-09 | 2012-10-10 | 武田薬品工業株式会社 | 固形製剤 |
| DE602006006712D1 (de) * | 2005-08-18 | 2009-06-18 | Hoffmann La Roche | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren |
| US20070077310A1 (en) * | 2005-10-03 | 2007-04-05 | University Of Tennessee Research Foundation | Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species |
| ATE507222T1 (de) * | 2005-11-30 | 2011-05-15 | Hoffmann La Roche | 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren |
| CA2630270A1 (en) * | 2005-11-30 | 2007-06-07 | F. Hoffmann-La Roche Ag | 5-substituted indole-2-carboxamide derivatives |
| DE602006020482D1 (de) * | 2005-11-30 | 2011-04-14 | Hoffmann La Roche | 1,5-substituierte indol-2-yl amidderivative |
| ES2333672T3 (es) * | 2005-12-09 | 2010-02-25 | F. Hoffmann-La Roche Ag | Derivados de amida triciclica para tratamiento de obesidad. |
| CN101326187A (zh) * | 2005-12-15 | 2008-12-17 | 霍夫曼-拉罗奇有限公司 | 吡咯并[2,3-c]吡啶衍生物 |
| BRPI0619985A2 (pt) * | 2005-12-16 | 2011-10-25 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, de obesidade e de diabetes do tipo ii em um ser humano ou animal e usos dos compostos |
| EP1803714A1 (de) * | 2005-12-27 | 2007-07-04 | KRKA, tovarna zdravil, d.d., Novo mesto | Verfahren zur Herstellung kristalliner Formen von Orlistat |
| BRPI0707916A2 (pt) * | 2006-01-13 | 2011-05-17 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e uso destes compostos |
| KR101047274B1 (ko) * | 2006-01-23 | 2011-07-06 | 에프. 호프만-라 로슈 아게 | Ｈ3 수용체 활성을 갖는 사이클로헥실 설폰아마이드 유도체 |
| US7432255B2 (en) * | 2006-05-16 | 2008-10-07 | Hoffmann-La Roche Inc. | 1H-indol-5-yl-piperazin-1-yl-methanone derivatives |
| EP2032554A1 (de) * | 2006-05-30 | 2009-03-11 | F. Hoffmann-Roche AG | Piperidinylpyrimidinderivate |
| EP1872777A1 (de) * | 2006-06-27 | 2008-01-02 | LEK Pharmaceuticals D.D. | Pharmazeutische Zusammensetzung enthaltend Tetrahydrolipstatin |
| US7514433B2 (en) | 2006-08-03 | 2009-04-07 | Hoffmann-La Roche Inc. | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives |
| US20080146559A1 (en) | 2006-12-08 | 2008-06-19 | Li Chen | 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives |
| TR200607613A2 (tr) * | 2006-12-29 | 2008-07-21 | NOBEL İLAÇ SAN.ve TiC.A.Ş. | Lipaz inhibitörü içeren farmasötik formülasyonlar |
| SI2002825T1 (sl) * | 2007-06-14 | 2013-10-30 | Krka | Farmacevtski sestavki, ki obsegajo orlistat |
| EA201070378A1 (ru) * | 2007-09-17 | 2010-08-30 | Др. Редди`С Лабораторис Лтд. | Фармацевтические составы орлистата |
| WO2009044380A2 (en) | 2007-10-05 | 2009-04-09 | Ranbaxy Laboratories Limited | Formulations containing orlistat particles having controlled particle size |
| US20100317642A1 (en) * | 2007-10-15 | 2010-12-16 | Inventis Dds Pvt Limited | Pharmaceutical composition of orlistat |
| US8298583B2 (en) | 2007-10-19 | 2012-10-30 | Monosol Rx, Llc | Film delivery system for tetrahydrolipstatin |
| US20090220593A1 (en) * | 2008-01-29 | 2009-09-03 | Gulati Inder | Extended release dosage forms of quetiapine |
| PL216542B1 (pl) | 2008-03-20 | 2014-04-30 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku |
| US8309107B2 (en) * | 2008-10-06 | 2012-11-13 | Banner Pharmacaps, Inc. | Stable solutions of orlistat for pharmaceutical dosage forms |
| BRPI0901602B8 (pt) * | 2009-04-03 | 2021-05-25 | Ems S/A | formulação farmacêuticas |
| MX342962B (es) * | 2009-09-18 | 2016-06-07 | Teva Pharmaceuticals Holdings Mexico S A De C V | Composicion farmaceutica para bajar de peso y procedimiento para obtener la misma. |
| UA107369C2 (en) * | 2010-02-01 | 2014-12-25 | Lab Bago S A | Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process |
| RU2441654C2 (ru) * | 2010-02-17 | 2012-02-10 | Лабораториос Баго С.А. | Фармацевтическая композиция с активностью против ожирения, включающая премикс чистого орлистата, и способ ее изготовления |
| US20120039999A1 (en) | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| US20120040008A1 (en) | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
| US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
| PL2720723T3 (pl) * | 2011-06-15 | 2018-10-31 | Synthon Bv | Stabilizowana kompozycja worykonazolu |
| MX2014000419A (es) | 2011-07-15 | 2014-09-22 | Nusirt Sciences Inc | Composicones y metodos para modular trayectorias metabolicas. |
| CN102362863B (zh) * | 2011-11-21 | 2013-06-12 | 山东新时代药业有限公司 | 一种含奥利司他的制剂及其制备方法 |
| GB201122213D0 (en) * | 2011-12-23 | 2012-02-01 | Norgine Bv | Compositions |
| NL2009995C2 (en) * | 2011-12-23 | 2013-09-18 | Norgine Bv | Compositions. |
| WO2013092786A1 (en) | 2011-12-23 | 2013-06-27 | Norgine B.V. | Compositions comprising cetilistat |
| US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
| JP2015509976A (ja) * | 2012-03-13 | 2015-04-02 | ピラマル エンタープライジーズ リミテッド | 代謝障害の治療用薬草組成物 |
| BR112015010947A2 (en) | 2012-11-13 | 2018-06-05 | Nusirt Sciences, Inc. | compositions and methods for increasing energy metabolism. |
| DE202012104963U1 (de) | 2012-12-19 | 2013-01-14 | Norgine B.V. | Cetilistat aufweisende Zusammensetzungen |
| SG11201507046UA (en) | 2013-03-15 | 2015-10-29 | Nusirt Sciences Inc | Leucine and nicotinic acid reduces lipid levels |
| CN104740637A (zh) * | 2013-12-31 | 2015-07-01 | 北京科信必成医药科技发展有限公司 | 一种稳定的奥利司他口服制剂及其制备方法 |
| CA2939833A1 (en) | 2014-02-27 | 2015-09-03 | Nusirt Sciences, Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
| US10743813B2 (en) | 2014-09-11 | 2020-08-18 | Rattan Nath | Diabetes control using postprandial feedback |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| CN122182527A (zh) | 2016-05-05 | 2026-06-12 | 阿奎斯蒂弗医疗股份有限公司 | 增强递送的肾上腺素组合物 |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| CN108785272B (zh) * | 2018-09-04 | 2019-04-09 | 中山万汉制药有限公司 | 一种奥利司他软胶囊及其制备方法 |
| CN115105476B (zh) * | 2021-03-23 | 2023-11-14 | 山东新时代药业有限公司 | 一种奥利司他冻干口服制剂及其制备工艺 |
| WO2023076281A1 (en) | 2021-10-25 | 2023-05-04 | Aquestive Therapeutics, Inc. | Oral and nasal compositions and methods of treatment |
| CN115300479A (zh) * | 2022-08-23 | 2022-11-08 | 宁波高新区美诺华医药创新研究院有限公司 | 奥利司他胶囊制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| JPH04198129A (ja) * | 1990-11-28 | 1992-07-17 | Sumitomo Pharmaceut Co Ltd | 活性型ビタミンｄ↓３類含有組成物 |
| CA2098167C (en) * | 1992-06-24 | 2006-12-19 | Dorothea Isler | Foodstuffs and feedstuffs containing a lipase inhibitor |
| CA2128044C (en) * | 1993-08-05 | 2007-02-20 | Klaus-Dieter Bremer | Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor |
-
1998
- 1998-01-06 US US09/003,137 patent/US6004996A/en not_active Expired - Lifetime
- 1998-01-24 RU RU98120492/14A patent/RU2170579C2/ru active
- 1998-01-24 DE DE69800639T patent/DE69800639T2/de not_active Expired - Lifetime
- 1998-01-24 SI SI9830023T patent/SI0921796T1/xx unknown
- 1998-01-24 DK DK98905346T patent/DK0921796T3/da active
- 1998-01-24 EP EP98905346A patent/EP0921796B1/de not_active Expired - Lifetime
- 1998-01-24 CA CA002258095A patent/CA2258095C/en not_active Expired - Lifetime
- 1998-01-24 YU YU49698A patent/YU49423B/sh unknown
- 1998-01-24 AU AU60972/98A patent/AU713192B2/en not_active Expired
- 1998-01-24 CZ CZ19983528A patent/CZ287154B6/cs not_active IP Right Cessation
- 1998-01-24 IL IL12690298A patent/IL126902A/en not_active IP Right Cessation
- 1998-01-24 PT PT98905346T patent/PT921796E/pt unknown
- 1998-01-24 ID IDW980113D patent/ID26509A/id unknown
- 1998-01-24 NZ NZ332659A patent/NZ332659A/xx not_active IP Right Cessation
- 1998-01-24 ES ES98905346T patent/ES2156028T3/es not_active Expired - Lifetime
- 1998-01-24 AT AT98905346T patent/ATE200027T1/de active
- 1998-01-24 HU HU0001468A patent/HU225035B1/hu unknown
- 1998-01-24 CN CNB988003694A patent/CN1193752C/zh not_active Expired - Lifetime
- 1998-01-24 WO PCT/EP1998/000395 patent/WO1998034607A1/en not_active Ceased
- 1998-02-02 PE PE1998000070A patent/PE57599A1/es not_active IP Right Cessation
- 1998-02-03 AR ARP980100472A patent/AR010704A1/es unknown
- 1998-02-03 MY MYPI98000418A patent/MY118371A/en unknown
- 1998-02-04 HR HR980057A patent/HRP980057B1/xx not_active IP Right Cessation
- 1998-02-04 CO CO98005480A patent/CO4920214A1/es unknown
- 1998-02-04 UY UY24875A patent/UY24875A1/es not_active IP Right Cessation
- 1998-02-05 MA MA24956A patent/MA24466A1/fr unknown
- 1998-11-16 NO NO19985337A patent/NO320445B1/no not_active IP Right Cessation
-
2001
- 2001-06-18 GR GR20010400907T patent/GR3036064T3/el unknown
-
2002
- 2002-04-05 CY CY0200014A patent/CY2264B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU713192B2 (en) | Tetrahydrolipstatin containing compositions | |
| KR100365572B1 (ko) | 서방성조성물및약학조성물의제조방법 | |
| KR100563342B1 (ko) | 맛이 차단된 약학 조성물 | |
| US6063313A (en) | Process for the preparation of fine particle pharmaceutical formulations | |
| KR101141508B1 (ko) | 판토프라졸 복합 미립자 제형 | |
| US6368622B2 (en) | Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption | |
| AU764280B2 (en) | Process for the preparation of pellets with a content of up to 90 wt. per cent of a pharmaceutical active ingredient | |
| EP1256338B1 (de) | Verfahren zur Herstellung von Formulierungen zur Direkttablettierung | |
| UA82268C2 (uk) | Гранули, що містять гідрохлорид венлафаксину, та спосіб їх виготовлення | |
| WO1995018602A1 (en) | ORAL DOSAGE FORM OF DESMOPRESSIN (dDAVP) | |
| Goskonda et al. | Development of matrix controlled release beads by extrusion-spheronization technology using a statistical screening design | |
| CZ20032138A3 (cs) | Způsoby a prostředky pro zeslabení chuti farmaceuticky aktivních činidel | |
| JP3059149B2 (ja) | テトラヒドロリプスタチン含有組成物 | |
| MXPA98009224A (en) | Tetrahydrolipstatin containing compositions | |
| JP5134818B2 (ja) | 脂質制御薬物製剤の製造のための方法 | |
| HK1021313B (en) | Tetrahydrolipstatin containing compositions | |
| TW533082B (en) | Tetrahydrolipstatin containing compositions | |
| PL203578B1 (pl) | Kompozycja farmaceutyczna | |
| SA98190009B1 (ar) | تركيبات متوية على رابع هيدروليبستاتين tetrahydrolipstatin | |
| BG62316B1 (bg) | фармацевтични форми с постоянно освобождаване и метод за получаването им |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |